Cilcare

About the deal

Montpellier and Osaka, June 6th, 2024 – Cilcare, a leading biotech company specializing in auditory sciences, is pleased to announce a landmark agreement with Shionogi, an impact-driven pharmaceutical company. This exclusive option agreement grants Shionogi the right to license global rights to CIL001 and/or CIL003, two promising drug candidates aimed at treating hearing disorders, with a particular focus on addressing the increasing prevalence of hidden hearing loss and tinnitus.

Under the terms of the agreement:
• Shionogi will receive an exclusive option to license global rights to CIL001 and/or CIL003.
• Cilcare will receive an upfront payment of €15 million.
• Cilcare is eligible to receive up to €400 million in milestone payments upon successful
development and commercialization of the drug candidates.
• Shionogi will decide whether to exercise the option right based on the results of the Phase
2a studies of CIL001 and preclinical study data of CIL003, both to be conducted by Cilcare.

Driven by its pioneering approaches from preclinical research to drug development, which harness AI-driven auditory markers known as Digital Auditory Signatures, Cilcare is dedicated to advancing therapies for auditory-related diseases. The agreement with Shionogi underscores Cilcare’s commitment to external innovation and collaboration to address critical unmet needs in hearing disorders.